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Abstract 
Saxitoxin (STX) is a low molecular weight neurotoxin mainly produced by certain marine 
dinoflagellates that, along with its family of similarly related paralytic shellfish toxins, 
may cause the potentially fatal intoxication known as paralytic shellfish poisoning. 
Illness and fatality rates are low due to the effective monitoring programs that 
determine when toxins exceed the established regulatory action level and effectuate 
shellfish harvesting closures accordingly. Such monitoring programs rely on the ability to 
rapidly screen large volumes of samples. Many of the screening assays currently 
available employ antibodies or live animals. This research focused on developing an 
analytical recognition element that would eliminate the challenges associated with the 
limited availability of antibodies and the use of animals. Here we report the discovery of 
a DNA aptamer that targets STX. Concentration-dependent and selective binding of the 
aptamer to STX was determined using a surface plasmon resonance sensor. Not only 
does this work represent the first reported aptamer to STX, but also the first aptamer to 
any marine biotoxin. A novel strategy of using a toxin-protein conjugate for DNA 
aptamer selection was successfully implemented to overcome the challenges associated 
with aptamer selection to small molecules. Taking advantage of such an approach could 
lead to increased diversity and accessibility of aptamers to low molecular weight toxins, 
which could then be incorporated as analytical recognition elements in diagnostic assays 
for foodborne toxin detection. The selected STX aptamer sequence is provided here, 
making it available to any investigator for use in assay development for the detection of 
STX.  
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1. Introduction 
 Saxitoxin (C10H17N7O4) is a low molecular weight toxin with a mass of 299.29 g mol
-
1
. One of the most harmful marine toxins, saxitoxin (STX) is primarily produced by 
several dinoflagellates as well as certain cyanobacteria (Deeds et al., 2008). Along with 
dozens of related congeners, STX makes up a suite of neurotoxins, which is referred to 
as paralytic shellfish toxins (PSTs) and are responsible for the human syndrome paralytic 
shellfish poisoning (PSP; Etheridge, 2010). Molluscan bivalves represent the major 
vectors of PSTs to humans given their capacity to filter feed and accumulate high 
concentrations of the toxins; however, numerous non-traditional vectors such as crabs, 
lobster, and carnivorous snails have also been identified (Deeds et al., 2008). Despite 
seasonal toxic algal blooms in certain geographic regions, PSP cases are rare because of 
the effective biotoxin monitoring programs that have been implemented. In the United 
States, shellfish growing areas are closed to harvesting when toxins are found to be 
higher than the regulatory action level of 80 µg STX equivalents per 100 g tissue.  
 The longstanding regulatory method for testing overall PSP toxicity is the mouse 
bioassay (MBA, AOAC Official Method of Analysis [OMA] 959.08); however, it has 
received much criticism for ethical reasons as well as a host of other issues including 
poor specificity, high cost, and high variability (Etheridge, 2010). Thus, recent emphasis 
has been placed on developing screening assays for PSTs that could reduce animal usage 
and provide a means of rapid, high throughput testing. Screening assays generally rely 
on incorporating analyte recognition elements such as native receptors (i.e., sodium 
channels) and produced biorecognition molecules (i.e., antibodies). Yet numerous 
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challenges remain for existing analytical recognitions elements (notably antibodies), 
including limited availability, cost, and the continued use of animals for their 
production. This research sought to develop a new analytical recognition element for 
STX that was cost effective, did not employ the use of animals for production, and was 
widely available for use by the marine toxin community for assay development.  
 Aptamers are nucleic acids or peptides that are selected in vitro to bind to a 
target with high affinity and specificity due to the tertiary structure formed (Ellington 
and Szostak, 1990; Tuerk and Gold, 1990; Bunka and Stockley, 2006). These short 
ribonucleic acid (RNA) or single-stranded deoxyribonucleic acid (ssDNA) analytical 
recognition elements are discovered from a starting random library of 10
12
 - 10
15
 
oligonucleotide sequences via an iterative process known as systematic evolution of 
ligands by exponential enrichment (SELEX; Ellington and Szostak, 1990; Tuerk and Gold, 
1990). Separation of target bound and unbound oligonucleotides has been performed 
using strategies such as affinity chromatography (Liu and Stormo, 2005), filtration 
(Schneider et al., 1993), SPR sensors (Misono and Kumar, 2005), and magnetic bead 
immobilization (Bruno and Kiel, 2002; Stoltenburg et al., 2005). Selected aptamers have 
been demonstrated for use in assays and platforms that have traditionally employed 
antibodies as analytical recognition elements. Aptamers display several important 
advantages over antibodies, including stability, lower cost, ease of production, and 
batch-to-batch consistency (Jayasena, 1999; Tombelli et al., 2005; Song et al., 2012). 
Further, and perhaps most important, aptamers do not depend on animal usage (live 
animals, cell lines, or in vivo conditions), either for development or production, making 
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them an ethically favorable choice over antibodies. Another feature of aptamers is that 
they can be easily modified via simple chemical modifications without compromising 
their potential for binding to the target, thereby allowing for a wide range of 
applications and manipulation for use with a variety of platforms (Jayasena, 1999; Song 
et al., 2012). 
 Since their discovery, aptamers have been applied to different classes of targets: 
small molecules (including organic dyes, metals, drugs, carbohydrates, amino acids, 
nucleotides, and peptides), proteins (including enzymes, antibodies, gene regulatory 
factors, and lectins), as well as viruses and pathogenic bacteria (see reviews by 
Jayasena, 1999; Stoltenburg et al., 2007). Regardless of the class and size of the desired 
target, there are a number of molecular features that determine the ease with which 
aptamers with high specificity can be generated. The target should be present in high 
concentrations and with high purity. Ideal target candidates include aromatic 
compounds and hydrogen bond donors and acceptors (Stoltenburg et al., 2007). 
Furthermore, the molecule must be amenable to the method used to separate target 
bound/unbound oligonucleotides. In this study, a hapten-carrier complex employed for 
STX antibody production was used for aptamer selection. This novel strategy of using a 
toxin-protein conjugate for DNA aptamer selection was implemented to overcome the 
challenges associated with discovering aptamers to low molecular weight targets, 
analogous to the use of hapten-carrier complexes for enhancing immunogenicity for 
antibody production against small molecules that alone are generally non-immunogenic. 
As such, we were able to take advantage of known chemistries for coupling the hapten-
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carrier conjugate to magnetic beads for SELEX and subsequent protein digestion 
strategies for assessing protocol performance (Figure 1). Counter-selection was 
conducted to remove any ssDNA that bound to the protein carrier, leaving only those 
sequences specific to the STX target. To the best of our knowledge, this is the first 
example of a SELEX method employing a hapten-carrier conjugate to discover an 
aptamer.  
 The goal of this research was to use STX conjugated to a protein carrier (keyhole 
limpet hemocyanin [KLH]) to develop an ssDNA aptamer that would bind to STX. Here 
we demonstrate (1) discovery of such an analytical recognition element using a hapten-
carrier conjugate, (2) concentration-dependent binding of the aptamer to surface-
bound STX, (3) aptamer binding to free STX, and (4) selectivity of binding of STX to the 
discovered aptamer, compared to other aptamers and random ssDNA sequences.  This 
novel approach to aptamer selection targeted for small molecule toxins offers a 
promising strategy that may be employed to generate a more extensive library of 
aptamers to marine toxins that can then be used for developing improved diagnostic 
assays.   
 
2. Experimental 
2.1 Development of toxin-protein conjugate  
 STX was conjugated to the carrier protein, keyhole limpet haemocyanin (KLH) via 
a modification of the Mannich reaction incorporating 2,2’-
(ethylenedioxy)bis(ethylamine), or Jeffamine, as a spacer compound in a similar manner 
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to that reported previously for bovine serum albumin (Campbell et al., 2007). In brief, 
Jeffamine was conjugated initially to the KLH via amine coupling. KLH (10 mg) was 
dissolved in 2-(N-morpholino) ethanesulfonic acid (MES) buffer (0.5 mL, 0.05 M MES, 
0.5M NaCl, pH 5). An aliquot (250 mL) of 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide (EDC, 20 mg) and 8 mg of N-hydroxysuccinimide 
(NHS) dissolved in MES buffer was added to the KLH and mixed for 5 min at room 
temperature. Then Jeffamine (50 mL, 1M) was added and the mixture allowed to react 
for 3 h at 20°C. The Jeffamine-KLH conjugate was purified using a PD-10 column (GE 
Healthcare) versus PBS (pH 7.2). Jeffamine-KLH (1 mg), STX (200 mg) and 2.5% 
formaldehyde (80 mL) were reacted, followed by dialysis over 24 h in 3 x 4 L of 0.15 M 
saline solution. 
2.2 STX-Jeffamine-KLH magnetic bead coupling and verification 
 Following the Dynabeads Co-Immunoprecipitation Kit (Life Technologies, Grand 
Island, NY) instructions, 30 µg of the STX-Jeffamine-KLH conjugate were covalently 
bound to 2 x 10
8
 (3 mg) Dynabeads
©
 M-270 Epoxy. After the coupling and washing 
steps, the coated beads were suspended at 6.7 x 10
5
 beads/µl, or 10 µg/µl, in PBS-T (10 
mM phosphate buffer, 2.7 mM KCl, 140 mM NaCl, 0.05% Tween-20, pH 7.4; Sigma, St. 
Louis, MO). A second batch of Dynabeads was coated with Jeffamine-KLH, as above, and 
was used for counter-selection.   
 To assess the success of the coupling procedure, forty microliters of ligand-
coupled Dynabeads (10 µg/µl) were transferred to a microcentrifuge vial and washed 3× 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 9 
with 100 µl of 50 mM ammonium bicarbonate (Sigma Aldrich, St. Louis, MO). The beads 
were resuspended in 50 µl of 9% acetonitrile in 50 mM ammonium bicarbonate. After 
the addition of 1 µg of the endoprotease trypsin, the reaction was allowed to proceed 
for 4 hours at 60 °C before being quenched with acetic acid (1% final concentration). 
Five micrograms of both standard KLH (Sigma) and STX-Jeffamine-KLH, as well as 400 µg 
of uncoupled Dynabeads were analyzed in the same fashion as positive and negative 
controls, respectively. The resultant tryptic peptides were analyzed by LC-MS/MS. 
Briefly, 10 µl of the peptide mixture was loaded onto a 0.15 x 100 mm nanoAcquity 
column (Water, Milford, MA) and washed with 90% mobile phase A (0.1 M acetic acid) 
at a flow rate of 1 µl/min. The bound peptides were eluted with the following gradient:  
0 – 1 min, 20% mobile phase B (0.1 M acetic acid in acetonitrile); 1 – 10 min, 40% mobile 
phase B; 10 – 11 min, 70% mobile phase B. The eluate was analyzed by a linear ion trap 
(LTQ) mass spectrometer (Thermo Fisher, Waltham, MA) with a data dependent 
acquisition of 3 MS/MS scans following a survey scan. 
2.3 Aptamer development (SELEX)  
The method used by DeGrasse (2012), as adapted from Murphy et al. (2003),
 
was 
followed to develop the STX aptamer. The library consisted of a central string of 40 
randomized nucleotides that were flanked by defined primer binding regions necessary 
for polymerase chain reaction (PCR) amplification. The library template was synthesized 
(1 µmole scale) with machine mixing for the bases within the center random sequence 
domain, and purified using polyacrylamide gel electrophoresis (PAGE) by Integrated 
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DNA Technologies (IDT, Coralville, IA). Forward and reverse primers were also generated 
by IDT (Table 1), as were reverse primers with a 5’ biotin label.  
 Ten rounds of aptamer selection were conducted starting with 5 nmoles (~3 x 
10
15
 different ssDNA sequences) of the library and 50 µl of STX-Jeffamine-KLH coupled 
beads (3.35 x 10
7
, Table 2) and following the SELEX protocol of DeGrasse (2012). This 
included running two PCRs per round using the same primers. Counter-selection rounds 
were included using Jeffamine-KLH coupled beads (no STX) for 6 of the 10 rounds. 
Otherwise, with the exception of performing 10 rounds of selection instead of the 14 
rounds conducted by DeGrasse (2012), all other details of the protocol were the same, 
including reagents, instruments, PCR conditions, and sequencing of final products (see 
below). All secondary PCR products were visualized, at the end of each round and again 
all together upon completion of the entire SELEX process, on a 4% E-Gel® (Life 
Technologies) with an E-Gel 25bp DNA ladder (Life Technologies). 
After round 10, the PCR product was cloned using the One Shot® Top10 E. coli 
with the TOPO® TA cloning vector (Life Technologies) according to manufacturer 
instructions. The E. coli (50 µl) was plated and grown overnight on pre-warmed (37 °C) 
LB agar plates containing 100 µg/ml ampicillin. The plates with a few hundred colonies 
were sent to GENEWIZ (South Plainfield, NJ) where 50 colonies were randomly selected 
for Sanger sequencing using the T3 sequencing primer that was present in the TOPO TA 
vector. The software program GeneiousPro (Drummond et al., 2010)
 
was used to 
remove the primer and plasmid sequences from the 42 successful sequences returned 
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from GENEWIZ. The trimmed 40 nt sequences were aligned in GeneiousPro and forced 
into zero gaps to directly compare each potential aptamer sequence nucleotide by 
nucleotide. Another alignment was generated in GeneiousPro using the ClustalW 
(Drummond et al., 2010)
 
algorithm that allowed for gaps to find potential motifs among 
the sequences. The settings in GeneiousPro were: cost matrix set to IUB (a scoring 
matrix), a gap open penalty of 9, and a gap extend cost of 3.  
 The structures of the resulting sequences were compared using the program 
mfold (Zuker, 2003) with the following settings: linear DNA fold, folding temperature set 
to 24 °C, ionic conditions for Na
+ 
and Mg
++
 were 140 and 0 mM, respectively (Peyret, 
2000), suboptimality was 5%, the window parameter was set to 2, and there was no set 
limit on the maximum distance between paired bases. If more than one structure was 
returned, the lowest ∆G in kcal/mol was selected for the comparison (SantaLucia, 1998).  
 
2.4 STX aptamer (APT
STX1
) binding evaluation with an SPR sensor 
 Standard laboratory materials for the SPR assays (e.g., sensor chips, amine 
coupling kit, and running buffers) were procured from Biacore (GE Healthcare, 
Piscataway, NJ). Nuclease free water (IDT) was used in the preparation of all reagents 
for SPR experiments. SPR running buffers (a. 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 
and 0.05% [v/v] surfactant P20 buffer [HBS-EP+] and b. 10 mM HEPES, 150 mM NaCl 
[HBS-N]) were prepared from 10× concentrates.   
The STX dihydrochloride used for chip formation and inhibition experiments was 
the FDA reference standard, currently available from the National Institute of Standards 
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and Technology (81.0 μg/mL free base in 20% ethanol/80% water). APT
STX1
,
 
APT
SEB1
, 
APT
RAND1
, and APT
RAND3 
were synthesized by IDT (See Table 1 for sequences) for use in 
the SPR assay. The sequences APT
RAND1
 and APT
RAND3 
were produced using a random 
sequence generator (http://www.bioinformatics.org/sms/index.html). 
 
2.4.1  STX aptamer (APT
STX1
) binding to surface-bound STX 
APT
STX1
 binding to STX was evaluated with a Biacore T200 surface plasmon 
resonance instrument (GE Healthcare). The STX sensor chip development and 
instrumentation parameters used herein were detailed in Yakes et al. (2011). Briefly, a 
CM5 sensor chip was prepared with three active channels via EDC/NHS activation, 
Jeffamine coupling, ethanolamine blocking, and STX coupling as well as one reference 
channel via EDC/NHS activation and ethanolamine blocking. Sensor chip activity was 
verified with a standard STX inhibition assay (Yakes et al., 2011). The chip performed as 
expected in the STX inhibition assay with 8 μg/mL burro anti-STX yielding 80 resonance 
units (RU) and a decreasing response with a corresponding increase in STX 
concentration. 
 Lyophilized APT
STX1 
was reconstituted in HBS-EP+ to a concentration of 100 μM, 
and then diluted to 240 μg/mL, heated at 95 °C for 5 min, and cooled on ice for 10 min 
prior to use. This stock was serially diluted in HBS-EP+ to yield 120, 60, 30, 15, 7.5, 3.75, 
1.88, 0.94, and 0.47 μg/mL of aptamer. A dilution of APT
STX1
 was injected over the 
sensor chip surface at 12 μL/min for 90 sec followed by a 30 sec dissociation period. 
After regeneration was performed with 50 mM NaOH for 60 sec, the next analysis cycle 
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was performed. Binding analysis was evaluated using the reference channel subtracted 
data to account for bulk refractive index variations. Within the sensorgram, a 5 sec 
window, 15 sec post-sample injection stop, was used to quantify the amount of APT
STX1
 
binding. Studies to determine specificity of the created sensor surface for the selected 
aptamer versus other ssDNA (APT
SEB1
, APT
RAND1
, and APT
RAND3
 each assayed at 10 µM) 
followed the same assay procedures. In addition, a modified domoic acid (DA) sensor 
chip (Traynor et al., 2006) was used to evaluate APT
STX1
 binding to a similar, small 
molecule marine toxin. Accurate chip performance was first ensured by evaluating the 
response with a DA antibody, and the DA substrate performed as expected in a DA 
inhibition assay with 1:200 anti-DA yielding 400 RU and a decreasing response with a 
corresponding increase in DA concentration. The STX aptamer (240 µg/mL) was exposed 
to the DA sensor chip for 90 sec at 12 µL/min. The curves were fit in GraphPad Prism (v. 
5.02, La Jolla, CA) with a one-site, total binding model. 
 
2.4.2  STX aptamer (APT
STX1
) binding to free STX 
 To perform studies on the aptamer binding to free STX, an antibody sensor 
substrate in conjugation with a direct toxin assay was performed. To create the 
substrate, a CM7 sensor chip was activated with EDC/NHS, polyclonal anti-STX (a 
generous gift from Beacon Analytical Systems [Saco, ME]; 75 µg/mL in pH 4.5, 10 mM 
sodium acetate buffer) was coupled, and ethanolamine was used to block remaining 
active sites. In addition, one reference channel was incorporated via EDC/NHS activation 
and ethanolamine blocking.  
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After determining assay conditions (HBS-N buffer, 50 µL/min flow rate, 180 sec 
contact time, and regeneration with 10 mM glycine HCl, pH 3.0 for 30 sec at 30 µL/min), 
direct toxin assays were performed.  First STX was injected over the sensor surface and 
then STX mixed with 50% of 240 µg/mL APT
STX1
, prepared as for previous SPR assays 
HBS-N buffer, was flowed over the antibody substrate. Final concentrations of STX in 
solution were 10,000, 5,000, 2,500, and 1,250 ng/mL. Curve fits were performed in 
GraphPad Prism using the log(agonist) vs. response (three parameters) function. 
 
3. Results and Discussion 
3.1 STX-Jeffamine-KLH magnetic bead coupling and verification 
 The coupling of KLH and STX-Jeffamine-KLH to the M-270 epoxy coated 
Dynabeads was successful, as demonstrated by proteomic analysis. During the LC-
MS/MS analysis of the standard KLH, an MS/MS spectrum was observed that resulted 
from the fragmentation of a peptide (811 m/z) that eluted from the column at 8.5 min 
(Figure 2A). This signature spectrum was also observed during the analysis of the 
Jeffamine-KLH-coupled and the STX-Jeffamine-KLH-coupled beads (Figure 2B and 2C, 
respectively).  This spectrum was not observed in the negative control (uncoupled 
beads).  
 
3.2 Aptamer development (SELEX)
 
Using the hapten-carrier conjugate as a target for SELEX also allowed us to apply 
an established protocol for discovering an aptamer to a protein target (DeGrasse, 2012) 
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to a small molecule target. This led to the efficient discovery of APT
STX1
 in 10 rounds of 
selection. To remove candidate sequences that bound either directly to Jeffamine-KLH 
or to the solid support, counter-selection was aggressively employed. Before proceeding 
with the next round of selection, it was imperative to check the product. After each of 
the ten rounds of SELEX, the quality and size of the resultant enriched library (78 bases) 
was confirmed by running the secondary PCR product on a 4% agarose gel. The 
presence of a band with the proper molecular weight (~78 bases) was the cue to 
proceed with the next round. Figure 3 illustrates the secondary products from all 
rounds. The success of the SELEX protocol was measured by the enrichment of a few 
sequences from a vast library of ~3 x 10
15
 different ssDNA sequences, in this case 31 out 
of 42 sequences were identical as is discussed below. 
Product from the final round of aptamer selection was sequenced to reveal the 
selected STX-binding aptamers. Of the fifty positive bacterial colonies selected for 
sequencing, 42 sequences were returned (84%). The sequences were trimmed to 
remove known plasmid and primer regions and were assessed for quality (i.e., proper 
length and sequence reaction confidence). The trimmed 40 nt sequences were aligned 
both with no gaps (Figure 4A) and with adjusted parameters that allowed for gaps using 
ClustalW (Figure 4B).  Out of the 42 sequences, 31 sequences, labeled APT
STX1
, were 
identical (73.8%) (Table 1 and Figure 4). The remaining 11 sequences were not 
significantly homologous to each other with a percent identity of 2.5% (Figure 4A). In 
fact, the only common base was at the first position; however, in the clustal alignment 
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(Figure 4B) a few common motifs were noted, but there were no more than 3 base runs 
and a small increase in percent identity to 7.7%.  
When synthesizing APT
STX1
 to evaluate binding, the priming sites were included, 
not only to enable PCR amplification, but also because the primers may play a role in 
structural stability or conformation. The sequence of APT
STX1
 was reported as 5’- GGT 
ATT GAG GGT CGC ATC CCG TGG AAA CAT GTT CAT TGG GCG CAC TCC GCT TTC TGT 
AGA TGG CTC TAA CTC TCC TCT (40 nt consensus in bold). The lowest free energy 
secondary structure of APT
STX1
 was predicted based on conditions during aptamer 
development (Figure 5). The estimated secondary structure for APT
STX1
 revealed four 
stem and loop segments, two involving the primers. The secondary structures of the 
other 11 sequences were also predicted. Again, the sequences were not significantly 
homologous to each other or APT
STX1
, but many (8) of the structures as predicted by 
mfold did include a stem and loop structure that could possibly play a role in aptamer 
function (data not shown).   
 
3.3 Binding evaluation of APT
STX1
 using SPR sensors 
     To demonstrate binding, varying concentrations of APT
STX1
 were exposed to a 
well-established STX sensor chip (Yakes et al., 2011; Yakes et al., 2012). While this chip 
has been optimized for PST antibody evaluation, binding of APT
STX1
 to the STX substrate 
was seen. APT
STX1
 bound to the STX surface, with the change in RU directly correlating 
with the amount of APT
STX1
 in solution (Figure 6). This increase in signal with an increase 
in solution APT
STX1
 concentration was reproducible, with low error and no dependence 
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on sample order or injection. As a negative control, the APT
STX1
 was exposed to the 
reference channel, and no change in response was observed (data not shown); as such, 
non-specific binding of APT
STX1
 to the chip was ruled out. 
To determine whether other ssDNA molecules would non-specifically bind to the 
sensor chip surface, several ssDNA sequences of the same length were exposed to the 
STX chip. APT
SEB1
, APT
RAND1
, and APT
RAND3
 did not exhibit binding to the STX sensor 
surface (data not shown), indicating that the STX sensor surface selectively bound to 
APT
STX1
. A modified DA sensor chip was used to evaluate specificity of APT
STX1 
binding 
relative to another small molecule marine toxin that often co-occurs in regions where 
STX may be present. After accurate chip performance was verified using an anti-DA/DA 
inhibition assay, APT
STX1
 was exposed to the DA sensor surface. Binding to the substrate 
was not observed (i.e., approx. 1 RU Fc2-1 response), thus indicating that APT
STX1
 did not 
cross-react with DA (data not shown) and further supporting that the selected aptamer 
was specific to STX. 
Finally, to show the selected aptamer has the ability to bind to free STX, an assay 
that detects STX from solution was developed. The highly-coupled antibody substrate 
(approx. 40,000 RU of anti-STX) has the ability to bind STX from solution and has an 
operating range of approx. 1,000 to 25,000 ng STX/mL with responses between 10 and 
50 RU. When the STX solutions were pre-mixed with APT
STX1
 and then injected over the 
antibody surface, no binding of STX to the sensor surface was observed (Figure 7). The 
lack of response in the presence of the aptamer indicated that the STX in solution was 
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bound to the aptamer and was not available to bind to the antibody surface. Together, 
these data demonstrated that the selected aptamer not only binds to surface-bound 
STX, but also to free STX in solution. Such assay versatility, along with potential 
selectivity, suggests that aptamers may be able to outcompete antibodies in small 
marine toxin diagnostics. Efforts to design detection systems with the STX aptamer as 
well as expand our aptamer library are underway.  
 
4. Conclusions 
To our knowledge, we have discovered the first aptamer to a marine toxin and 
demonstrated that it binds selectively to STX in a concentration-dependent manner. For 
discovery of APT
STX1
, we employed a novel approach of using a hapten-carrier conjugate 
as the SELEX target. Coupling a small molecule to a solid support often poses a challenge 
to aptamer development. In particular, it can be difficult to assess the efficiency of such 
a coupling reaction. To avoid such a challenge, we took advantage of a hapten-carrier 
(STX-Jeffamine-KLH) conjugate that was produced originally for antibody production. 
The conjugate essentially converted a small molecule (~299 Da) into a protein moiety 
(~350 kDa), thus allowing conventional surface chemistries (e.g., amine/epoxy reaction) 
to be used for coupling the conjugate to a solid support. Additionally, we were able to 
verify the coupling reaction to ensure that the paramagnetic beads were coated with 
the conjugate. This assessment was crucial given that the hapten-carrier reaction 
reduces the number of free amines on the carrier available for coupling to the epoxy 
active sites on the Dynabeads.  
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 This study represented the first step in aptamer development for marine toxins 
and resulted in a promising strategy for continued aptamer selections to target marine 
toxins. These aptamers can be developed in a very short period of time (weeks 
compared to the months required for antibody production), are inexpensive to produce, 
and have the potential for implementation into a wide range of detection assays and 
platforms. While antibodies are often proprietary, this work reports the sequence of the 
aptamer selected to STX, thereby making it available to any researcher who wishes to 
employ it as an analytical recognition element in their own assay development. Future 
research will include discovering aptamers to other relevant PSTs and incorporating 
these analytical recognition elements into operational assays. It is anticipated that the 
use of aptamers in marine toxin detection methods could reduce or eliminate animal-
based models, as well as the numerous challenges associated with antibody-based 
methods.  
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Figure captions: 
Fig. 1: Schematic of aptamer development. The iterative process began with the STX-
Jeffamine-KLH coupled magnetic beads being incubated with the random ssDNA 
library. Following incubation, bound versus unbound ssDNA were separated and 
then the bound ssDNA were eluted from the STX-Jeffamine-KLH coupled magnetic 
beads, replicated by PCR, and used as an enriched library for the next round of 
selection. During rounds 4-10 an additional step was included for counter-selection. 
Magnetic beads coupled to Jeffamine-KLH were incubated with the PCR product 
from the previous round. Only the ssDNA that did not bind to the beads coupled 
with Jeffamine-KLH were used for the next round of selection. This process consisted 
of a total of 10 rounds 
 
Fig. 2: LC-MS/MS confirmation of ligand coupling to Dynal M-270 expocy-coated 
beads. The MS/MS spectrum of parent ion 811 m/z was observed in (A) standard 
KLH, (B) KLH-coupled beads, and (C) STX-Jeffamine-KLH coupled beads. This 
spectrum was not observed with the negative control of uncoupled Dynabeads.  
 
Fig. 3: Gel image of all 10 rounds of aptamer selection showing the products from 
the 2
nd
 PCR. Lane 1 is the ladder (25bp-500bp), lane 2-11 are rounds 1-10 
respectively, and lane 12 is a no template control.  
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Fig. 4:  Alignments generated in GeneiousPro representing the 42 clonal sequences 
returned (with the primer and plasmid regions trimmed). Sequence 1 is APT
 STX1
 and 
represents 31 clones with 100% matches to each other. All other recovered 
sequences are shown (with no identical matches). Common bases are marked with a 
darker square. Panel A represents a manually edited alignment where each base was 
forced into position with no gaps. Panel B is a ClustalW alignment allowed for gaps 
to explore potential motifs. 
 
Fig. 5: Predicted folding and structure of APT
STX1
, as generated by the mfold web 
server (Zuker, 2003). Bases that were similar in all 12 sequences are highlighted in 
gray.  
 
Fig. 6: SPR calibration curves showing the concentration-dependent binding of the 
STX aptamer (APT
STX1
). (A) Raw response (in RU) from flow cell 2 with reference 
subtraction (flow cell 1) for a concentration series of APT
STX1
 and (B) average 
normalized response from four replicate measurements. Curves were fit in 
GraphPad Prism with a one-site, total binding model.  
 
Fig. 7: SPR calibration curves showing: (1) STX direct binding to an STX antibody 
sensor and (2) inhibition of STX binding when APT
STX1
 was added to the analyte 
solution prior to injection over the antibody substrate. Each data point is the 
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average response from two replicate measurements (standard deviation shown by 
the error bars) of blank subtracted data, normalized to STX 10,000 ng/mL. 
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Highlights: 
 
• We present the first reported aptamer selected to a marine biotoxin (saxitoxin). 
 
• A novel strategy of using a toxin-protein conjugate was utilized. 
 
• Initial step towards new aptamers and their application to marine toxin assays. 
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Table 1: The primer and library sequences used in this study as well as the sequence of 
the STX aptamer (APT
STX1
) discovered in this work. APT
STX1
 was reported in 31 out of 42 
sequences. Also two random sequences (APT
RAND1
 and APT
RAND3
) were generated and 
used for experiments to evaluate selectivity of discovered sequences to the target.  
Name Sequence Citation 
Forward 
Primer 
5’-GGT ATT GAG GGT CGC ATC  23 
Reverse 
Primer 
5’-AGA GGA GAG TTA GAG CCA 
TC 
23 
APT
LIB
 5’-GGT ATT GAG GGT CGC ATC-
N40-GAT GGC TCT AAC TCT CCT 
CT 
 23 
APT
STX1
 5’-GGT ATT GAG GGT CGC ATC 
CCG TGG AAA CAT GTT CAT TGG 
GCG CAC TCC GCT TTC TGT AGA 
TGG CTC TAA CTC TCC TCT 
This publication 
APT
RAND1
 5’-GGT ATT GAG GGT CGC ATC 
TAG TAG AAA AGT GCT GAG 
TAG TTT TAC CTG GTA GAT ATG 
CGA TGG CTC TAA CTC TCC TCT  
This publication 
APT
RAND3
 5’-GGT ATT GAG GGT CGC ATC This publication 
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CCT CAC TTA ACA GCC CGG TCA 
TGC TGA GTG TTA TTA GCT CGA 
TGG CTC TAA CTC TCC TCT 
APT
SEB1
 5’-GGT ATT GAG GGT CGC ATC 
CAC TGG TCG TTG TTG TCT GTT 
GTC TGT TAT GTT GTT TCG TGA 
TGG CTC TAA CTC TCC TCT 
23 
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Table 2: Values for the number of beads and incubation times used in each round. The 
values were modulated in later rounds to increase the stringency of the SELEX protocol. 
Round Counter-
Selection 
Beads 
Selection 
Beads  
Incubation 
Time (min) 
1 0 3.35 x 10
7
 30 
2-3 0 1.34 x 10
7
 10 
4-6 3.35 x 10
7
 6.7 x 10
6
 10 
7-9 3.35 x 10
7
 2.01 x 10
6
 10 
10 3.35 x 10
7
 6.7 x 10
5
 10 
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